NPPB and cancer: Cardiotoxicity from cancer therapy, leading to reduced LVEF, can result from various treatments. Despite elevated NT-proBNP levels, 43% with LVEF below 50% showed no NT-proBNP increase. Comprehensive monitoring includes biomarkers, clinical exams, ECG, and echocardiography for early myocardial dysfunction detection and timely intervention.